NASDAQ OMX

ZAGENO on Growth Trajectory - Startup Becoming #1 Online Marketplace for Life Science Research Products; Raises $8 Million

Dela

BOSTON, Mass., USA, and BERLIN, GERMANY, Oct. 25, 2017 (GLOBE NEWSWIRE) -- ZAGENO Inc., announces successful Series A investment of $8 Million US Dollars led by Capnamic Ventures, with Grazia Equity, lead investor in the seed round, also investing. The investment will be used to fuel growth in the key markets USA and Europe, by ramping up sales, marketing, and technical integration teams.


ZAGENO Launching a New Era of Digital Science and Research

"Just two years old, we are experiencing enormous traction, where global leaders in life science research, such as The Babraham Institute, choose to purchase life science research products through us," said Co-Founder and CEO of ZAGENO David Pumberger. "There is a vast need for digitalization in science and research! We founded ZAGENO with the vision of connecting scientists, administrative departments, and vendors of biotechnology products via one single platform, thereby creating a WIN-WIN-WIN-Situation for everybody involved. Nobody has dared to do that so far," he continued.

What is the WIN-WIN-WIN-situation for scientists, academic research institutes, researching companies, and equipment vendors? For the first time, ZAGENO enables scientists in their laboratories to choose crucial products directly via an online marketplace, from an extensive and high-quality product portfolio. Currently, researchers from 250+ leading research institutions in the U.S. and Europe compare products every day on ZAGENO for their experiments and order directly from across 650+ different vendors. This newly unveiled transparency is an absolute novelty in the biotech industry and saves costs as well as time for researchers.

ZAGENO enables straightforward integration of ordering and purchasing processes into existing software systems. And it is a milestone in the direction of bundled, and therefore, more-efficient, operation flows for academic research institutes and research companies alike. Biotechnology vendors benefit from the ZAGENO online-platform by reaching potential customers right at the buying/decision-making moments. They can also leverage ZAGENO as an additional digital sales channel to increase their reach in the key markets - USA and Europe. Further, the ZAGENO online-platform represents a valuable marketing tool to strengthen brand awareness and foster brand image and thus helps industry players to adapt to existing e-commerce models by increased customer service and content quality.

Commenting on The Babraham Institute's experience with ZAGENO, Michael Norden, the Institute's head of purchasing, said, "ZAGENO enables our 200+ scientists to choose and order life science research products from all vendors using one platform. This further streamlines our purchasing processes and allows us to gain full transparency on our spending. Ultimately, scientists focus on their research while complying with all purchasing requirements. We have found ZAGENO's customer service to be outstanding."

"ZAGENO combines an exceptional team and is the first to unlock an untapped billion dollar U.S. market," said Capnamic Ventures General Partner Christian Siegele.

Founding Partner of Grazia Equity Alec Rauschenbusch commented, "ZAGENO is fantastic. It's a true game-changer, helping the life science industry become more successful."           

ZAGENO's Pumberger added, "Together with our partners and the Series A funding, we will strengthen our position at the interface of technology and biotech, as well as reach our targeted growth in focus markets. We feel very fortunate to grow together with Capnamic Ventures and Grazia Equity and to benefit from their deep industry connections and insights. Consistent with entrepreneurial values, mindsets, and growth targets, we focus on fulfilling customers' needs on all sides of the platform!"

About Capnamic Ventures

Capnamic Ventures (www.capnamic.com) is one of Europe's leading early-stage Venture Capital firms, with offices in Berlin and Cologne. The VC invests most of its funds in tech startups in the German-speaking region. Capnamic also joins forces with international co-investors. All portfolio companies are supported through Capnamic's global network of investors and industry partners.

The vast expertise of the Capnamic team includes more than 70 investments, a high turnover of successful trade sales and IPOs, as well as a strong entrepreneurial track record within the investment team. The general partners are Jörg Binnenbrücker (@bibrue), Olaf Jacobi (@olafjacobi) and Christian Siegele.

For more details, visit capnamic.com or @Capnamic on Twitter.

About Grazia Equity

Grazia Equity, one of Germany's top venture capital firms, has been supporting a large number of mostly young companies, often from their foundation to the Initial Public Offering or eventual sale. Grazia's success derives from a partnership with extraordinarily strong entrepreneurial teams to turn them into international market leaders. In contrast to other venture capital firms Grazia has a solid permanent capital structure ("Evergreen"). Grazia's portfolio companies profit from the entrepreneurial background and the business development expertise of its partner team as well as a far-reaching international network. Being active in Germany, Europe and in the USA Grazia has invested early in category leaders such as Statista, Mister Spex, Conergy, Quantenna, and Yeay.

For more information, please visit grazia.com

About ZAGENO Inc.

Since its formation in 2015, ZAGENO Inc. sets new standards in the international biotech market. With the vision to offer an online marketplace connecting scientists, academic research institutes, and biotech manufacturers, ZAGENO grows exponentially and represents a milestone for the digitization of science and research. World-renowned research facilities use ZAGENO for ordering lab equipment and for optimizing internal processes. The start-up employs 35 staff members in Boston (USA) and Berlin (Germany). These two locations were selected to be close to centers known for research advancements and scientific breakthroughs. For more "EUREKA"-moments - welcome to ZAGENO: https://zageno.com/

Attachments:

A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/8f25a44f-43ac-4555-89c9-88e214485457

Attachments:

A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/4121b588-dce2-4b4c-81f5-1375ea13b05b

Attachments:

A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/b62c1ccf-4885-4563-813c-5f4596194fd2

Media Contact: Caroline Grossman
(781) 771-5579
Caroline@Mirepoixllc.com

Company Contact: Florian Wegener, MD, PhD, MBA, Chief Revenue Officer
ZAGENO Inc.
pr@zageno.com




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: ZAGENO, Inc. via Globenewswire

Om

NASDAQ OMX
NASDAQ OMX



Följ NASDAQ OMX

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från NASDAQ OMX

Crown Bioscience and Data Sciences International (DSI) Partner to Advance Metabolic Disease Research Using an Implanted Telemetry Device for Long-Term Blood Glucose Monitoring23.11.2017 14:00Pressmeddelande

SANTA CLARA, Calif., Nov. 23, 2017 (GLOBE NEWSWIRE) -- Crown Bioscience, a wholly-owned subsidiary of Crown Bioscience International (TWSE: ticker 6554) and a global drug discovery and development services company providing translational platforms to advance oncology, inflammation cardiovascular and metabolic disease research, announces the successful development of an enhanced method for preclinical obesity and type 2 diabetes studies in partnership with Data Sciences International (DSI). Crown Bioscience's clinically relevant models and DSI's HD-XG implantable glucose device combine to create a superior approach to preclinical metabolic disease research. Recently published work in the Journal of Endocrinological Investigation and Nature's Scientific Reports demonstrates the advantages of a new method using DSI's HD-XG implantable glucose device and Crown Bioscience's models of spontaneous and diet-induced diabetes. The HD-XG device allows for continuous, long-term measurement

LeoVegas AB: Nomination committed appointed for LeoVegas ahead of 2018 Annual General Meeting23.11.2017 11:50Pressmeddelande

In accordance with the principles for appointment of a nomination committee of LeoVegas AB (publ) ("the Company" or "LeoVegas") that were adopted by the Annual General Meeting on 17 May 2017, the Nomination Committee shall consist of four members appointed by the three largest shareholders as at 30 September 2017, together with the Chairman of the Board. Based on the above, the Nomination Committee ahead of the 2018 Annual General Meeting has been determined to consist of the following persons, who represent approximately 23% of the number of shares and votes in the Company as per 30 September 2017: Anders Fast, Nomination Committee chair, representing Gustaf Hagman Joachim Spetz, representing Swedbank Robur Fonder Dan-Alp Lindberg, representing Robin Ramm-Ericson Mårten Forste, Chairman of the Board The No

LeoVegas AB: Valberedning utsedd i LeoVegas inför årsstämma 201823.11.2017 11:50Pressmeddelande

Enligt de principer för valberedning i LeoVegas AB (publ) ("Bolaget" eller "LeoVegas") som antogs på årsstämman den 17 maj 2017 ska valberedningen bestå av fyra ledamöter utsedda av de tre största aktieägarna per den 30 september 2017, jämte styrelsens ordförande. Baserat på ovanstående har valberedningen inför årsstämman 2018 fastställts till att bestå av följande personer som tillsammans representerar cirka 23 procent av antalet aktier och röster i Bolaget per den 30 september 2017: Anders Fast, valberedningens ordförande och utsedd av Gustaf Hagman Joachim Spetz, utsedd av Swedbank Robur Fonder Dan-Alp Lindberg utsedd Robin Ramm-Ericson Mårten Forste, styrelseordförande Valberedningens förslag kommer att presenteras i kallelsen till årsstämman 2018 samt på bolagets hemsida, www.leovegasgroup.com.

Hemcheck Sweden AB: Viktigt patent beviljat av PRV23.11.2017 09:00Pressmeddelande

PRESSMEDDELANDE   Viktigt patent beviljas av PRV PRV, det svenska patent och registreringsverket, meddelar att HemChecks patentansökan gällande bolagets blodseparationsteknik kommer att beviljas för Sverige den 19 december 2017. Patentets publiceringsnummer kommer att bli 539853. -För HemCheck är patentet strategiskt mycket viktigt, eftersom det innefattar vår teknik för blodseparation. Det skyddar den teknik som gör att en ej definierad blodvolym kan användas i vårt engångstest och det är just det som gör vårt hemolystest så unikt, enkelt och användarvänligt - och dessutom mycket snabbt. I kombination med övriga patent har vi nu ett mycket bra skydd för den metod som HemChecks affärsidé i grunden bygger på, säger vd Annelie Brolinson i en kommentar. En internationell patentansökan har lämnats in för att söka skydd på övriga viktiga marknader.  För ytterligare information, kontakta: Hemcheck Sweden AB

BDA partners with government to attract cryptocurrency23.11.2017 06:25Pressmeddelande

HAMILTON, Bermuda, Nov. 23, 2017 (GLOBE NEWSWIRE) -- The Bermuda Business Development Agency (BDA) will take a lead role in an initiative launched by the Bermuda government today to accelerate the establishment and growth of digital currency business on the island. A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/457f43b9-d7bb-48f1-83e2-b856b33ebacc At a press conference held by Premier the Hon David Burt and National Security Minister the Hon Wayne Caines, the government announced the formation of a task force comprising two teams to advance Bermuda's regulatory environment as a destination for utility tokens, tokenised securities, cryptocurrencies, and coin offerings. BDA Consultant for Emerging Technologies John Narraway was named as chair of the Blockchain Business Development Working Group, while BDA Board member Lydia Dickens will chair the Blockchain Legal and Regulatory Working Group, of which

VistaJet Partners With Christie's for the Global Tour of The Collection of Peggy and David Rockefeller22.11.2017 11:39Pressmeddelande

The sale will be the most significant philanthropic auction ever presented LONDON, Nov. 22, 2017 (GLOBE NEWSWIRE) -- VistaJet, the first and only global private aviation company, announces today its worldwide sponsorship of the exhibition and tour of The Collection of Peggy and David Rockefeller, the most significant auction entirely dedicated to raising funds for philanthropic causes.  The sale, consisting of numerous categories, will be conducted by Christie's, the world's leading art business, and will include a highlights exhibition tour in Hong Kong, London, Los Angeles and New York. Photos accompanying this announcement are available at http://www.globenewswire.com/NewsRoom/AttachmentNg/c78fdce7-7651-42a8-a621-14088da2cc86 http://www.globenewswire.com/NewsRoom/AttachmentNg/33af2489-a9a8-4bbe-b5f7-78e4c1f29ca2 http://www.globenewswire.com/NewsRoom/AttachmentNg/a16c2

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum